Home >> Law >> Food & Beverage >>

DNAVEC Corporation - Product Pipeline Review - 2015

Published: May-2015 | Format: PDF | Global Markets Direct | Number of pages: 25 | Code: MRS - 19837

DNAVEC Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘DNAVEC Corporation - Product Pipeline Review - 2015’, provides an overview of the DNAVEC Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of DNAVEC Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of DNAVEC Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of DNAVEC Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the DNAVEC Corporation’s pipeline products

Reasons to buy

- Evaluate DNAVEC Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of DNAVEC Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the DNAVEC Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of DNAVEC Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of DNAVEC Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of DNAVEC Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
DNAVEC Corporation Snapshot 4
DNAVEC Corporation Overview 4
Key Information 4
Key Facts 4
DNAVEC Corporation - Research and Development Overview 5
Key Therapeutic Areas 5
DNAVEC Corporation - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
DNAVEC Corporation - Pipeline Products Glance 11
DNAVEC Corporation - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
DNAVEC Corporation - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
DNAVEC Corporation - Drug Profiles 14
DVC1-0101 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Gene Therapy for Glaucoma and Retinitis Pigmentosa 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
SeV-G 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
DNAVEC Corporation - Pipeline Analysis 18
DNAVEC Corporation - Pipeline Products by Target 18
DNAVEC Corporation - Pipeline Products by Route of Administration 19
DNAVEC Corporation - Pipeline Products by Molecule Type 20
DNAVEC Corporation - Pipeline Products by Mechanism of Action 21
DNAVEC Corporation - Recent Pipeline Updates 22
DNAVEC Corporation - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 24
Disclaimer 25

List of Tables
DNAVEC Corporation, Key Information 4
DNAVEC Corporation, Key Facts 4
DNAVEC Corporation - Pipeline by Indication, 2015 6
DNAVEC Corporation - Pipeline by Stage of Development, 2015 7
DNAVEC Corporation - Monotherapy Products in Pipeline, 2015 8
DNAVEC Corporation - Partnered Products in Pipeline, 2015 9
DNAVEC Corporation - Partnered Products/ Combination Treatment Modalities, 2015 10
DNAVEC Corporation - Phase II, 2015 11
DNAVEC Corporation - Phase I, 2015 12
DNAVEC Corporation - Preclinical, 2015 13
DNAVEC Corporation - Pipeline by Target, 2015 18
DNAVEC Corporation - Pipeline by Route of Administration, 2015 19
DNAVEC Corporation - Pipeline by Molecule Type, 2015 20
DNAVEC Corporation - Pipeline Products by Mechanism of Action, 2015 21
DNAVEC Corporation - Recent Pipeline Updates, 2015 22

List of Figures
DNAVEC Corporation - Pipeline by Top 10 Indication, 2015 6
DNAVEC Corporation - Pipeline by Stage of Development, 2015 7
DNAVEC Corporation - Monotherapy Products in Pipeline, 2015 8
DNAVEC Corporation - Partnered Products in Pipeline, 2015 9
DNAVEC Corporation - Pipeline by Top 10 Target, 2015 18
DNAVEC Corporation - Pipeline by Top 10 Route of Administration, 2015 19
DNAVEC Corporation - Pipeline by Top 10 Molecule Type, 2015 20
DNAVEC Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015 21

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing